Last updated 2026-08-21
- Raised $25M Series A led by IBF, Nov 2022
- Raised $10M A Round Extension led by Guangzhou-Israel Biotechnology Fund (GIBF), May 2024
- Raised $6M Seed round led by aMoon Velocity, Jul 2020
Total raised
$41.0M
Last: Undisclosed Round 2024-05
Stage
Series A
Founded
2017
Headcount
13
HQ
Jerusalem, Israel
Sector
Biotechnology
About
Nectin Therapeutics is a clinical-stage biotechnology company focused on transforming the lives of cancer patients by developing next-generation immune-oncology (IO) and antibody-drug conjugate (ADC) therapies. The company's therapies aim to overcome resistance to existing IO treatments by leveraging unique insights into the nectin pathways. Nectin Therapeutics was established in 2017 based on research conducted at the Hebrew University of Jerusalem and the University of Rijeka. Their technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates. The company has offices in Jerusalem, Israel, and Fort Lee, New Jersey, USA.
Funding history · 5 rounds · $41.0M total
5 events/rounds · $41.0M Total Funding: $41.0M in Private Equity
May 2024
★ Guangzhou-Israel Biotechnology Fund (GIBF)
Mar 2024
★ European Innovation Council (EIC) Accelerator
May 2023
Nov 2022
Jul 2020
Headcount over time
13 employees (2026-09) · 1 point
Offices
Jerusalem, Israel · HQ / main office
Show all offices (1 more)
- Fort Lee, United States
Q&A
- What is Nectin Therapeutics' primary focus?
- Nectin Therapeutics is a clinical-stage biotechnology company focused on developing next-generation immune-oncology (IO) and antibody-drug conjugate (ADC) therapies for cancer patients.
- When was Nectin Therapeutics founded?
- Nectin Therapeutics was established in 2017 based on research conducted at the Hebrew University of Jerusalem and the University of Rijeka.
- How many employees does Nectin Therapeutics currently have?
- Nectin Therapeutics has 11-50 employees.
- What was Nectin Therapeutics' most recent funding round?
- In May 2024, Nectin Therapeutics raised $10,000,000 in an A Round, with.
- Which investors participated in Nectin Therapeutics' Series A funding round in November 2022?
- In November 2022, Nectin Therapeutics raised $25,000,000 in an A Round, with IBF.
- What was the amount of the grant received by Nectin Therapeutics in August 2024?
- In August 2024, Nectin Therapeutics received a grant of $2,699,999.
- Who are the co-founders of Nectin Therapeutics?
- The co-founders of Nectin Therapeutics are Ofer Mandelboim and Pini Tsukerman.
- What is the status of Nectin Therapeutics' product development?
- Nectin Therapeutics' products are in the clinical trial stage.
- What was Nectin Therapeutics' collaboration with Merck announced in February 2023?
- In February 2023, Nectin Therapeutics announced a collaboration with Merck on a clinical trial of their anti-PVR antibody NTX1088 in combination with KEYTRUDA® (pembrolizumab) for patients with locally advanced and metastatic solid tumors.
Team · 15
Pini Tsukerman
Founder · Chief Scientific Officer
Ofer Mandelboim
Founder · Scientific Advisory Board
Keren Paz
Chief Development Officer
Eric Rowinsky
Acting Chief Medical Officer
Guy Cinamon
Vice-President, R&D
Lani Questembert
Director
Eyal Lifschitz
Director
Samuel Moed
Director
David Sidransky
Director
Prof. Samir Khleif
Scientific Advisory Board
Fred Hirsch
Scientific Advisory Board
Morris Rosenberg
Scientific Advisory Board
Stipan Jonjic
Scientific Advisory Board
Fabian Tenenbaum
CEO
Sectors & technology
Primary sector
Biotechnology
Technologies
Target customers
Business model
B2B
Highlights
1 Patents
Tags
biotechnologypharmaceuticalsoncologyimmunologycancer-therapycancerantibodiespatientsdrug-deliverytreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nectintx.com |
|---|---|
| linkedin.com/company/69206104 |
Identifiers & details
| Legal name | Nectin Therapeutics Ltd. |
|---|---|
| Founded | 2017 |
| Employees (exact) | 13 |
| Offices | Fort Lee |
Radar intelligence
Patents
| EPO | 6 |
|---|
Web history (Wayback)
| Domain | nectintx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515675890 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-06-19 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 2 — violation (1), annual_report (1) |
| Registered address | פארק ההי-טק קמפוס גבעת רם - ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-07-21 | עדכון הפרה |
| 2026-07-21 | דו~ח שנתי |